Sales forecast of ulcerative colitis medications worldwide 2021-2026
In 2026, the ulcerative colitis medication Rinvoq by AbbVie is forecasted to generate 5.1 billion U.S. dollars in sellside revenue. This statistic illustrates the sales forecast of select medications for ulcerative colitis worldwide from 2021 to 2026.